tbuckley/cabot-search huggingface dataset:
Providing information and support on all aspects of breast health and breast cancer in Ireland
Authors: N. Fitzgibbon, A. Langtry
Journal: Journal of Clinical Oncology (2006)

10766 In 2001 the Irish Cancer Society launched Action Breast Cancer (ABC) to provide breast cancer information and support. ABC’s services are free, confidential and accessible and include a national helpline, patient education, one-to-one support, health promotion, research, advocacy, and professional support. Over the last five years, we have been continually developing our services to the public, at the heart of which is the Freefone Helpline (1800 30 90 40). The Helpline is staffed by specialist cancer nurses who offer information, support, and appropriate referral for women who are concerned about breast health, women who have been diagnosed with breast cancer, their families and carers, and healthcare professionals. In order to meet the need for clear, concise information, we are continually producing and updating literature and supporting materials. This includes a series of factsheets on all aspect of a breast cancer diagnosis including the different aspects of living with the disease. In January 2005, we launched a programme to address the unique needs of younger women with breast cancer. Services include conferences for younger women, a specialist nurse, and the selection and training of younger Reach to Recovery volunteers. Professional support is also a key element of ABC’s service. Most recently we have developed a workshop for nurses working in oncology to improve communication with breast cancer patients around sexuality. ABC’s annual Breast Cancer Awareness Month campaign takes place in October. A high profile advertising campaign and a nationwide roadshow are just two of the many mediums used to target Irish women in order to make them breast aware for life. Throughout the year, ABC is constantly seeking to raise awareness in communities and workplaces across the country by organising presentations about breast awareness, screening and early detection. Now that we have firmly established ourselves as the leading provider of breast cancer information and support, we have started to significantly develop our advocacy programme, and we are currently working on ensuring that the national breast screening programme will be fully rolled out by the end of 2007. We are also undertaking major nationwide research into the provision, supply and fitting of breast prostheses. No significant financial relationships to disclose.
Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI).
Authors: Dianna Shipley, John D. Hainsworth, Tarek Mekhail, John D. Zubkus, Douglas B. Flora, Davey B. Daniel, David Michael Waterhouse, Donald Gravenor, Howard A. Burris, Frank A. Greco, David R. Spigel
Journal: Journal of Clinical Oncology (2012)

7100 Background: Amrubicin is a novel anthracycline associated with high objective response rates (ORR) in patients (pts) with relapsed SCLC. Amrubicin improved the ORR and progression-free survival (PFS) in relapsed SCLC vs. topotecan, but not overall survival (OS) in a phase III study. Amrubicin with cisplatin/carboplatin for elderly Japanese pts was safe and active. We conducted a multicenter phase II study evaluating amrubicin and carboplatin in newly diagnosed ES-SCLC. Methods: Eligible pts had untreated ES-SCLC, measurable/evaluable disease (RECIST v. 1.1) and an ECOG PS &lt;2. Pts received 4 cycles of amrubicin 30 mg/m 2 on days 1-3 and carboplatin AUC=5 both IV day 1 every 21 days with restaging every 6 weeks. Pegfilgrastim 6 mg sq was administered on day 4 of each cycle. The primary endpoint was 1-year OS. Secondary endpoints included ORR, PFS, OS, and toxicity. Results: 78 pts were enrolled from 3/2010 to 7/2011. Baseline characteristics included: median age 65 yrs (range 45-84); 56% female. 64% completed 4 cycles of treatment. Eleven (14%) pts showed complete responses and 47 (60%) pts partial responses, for an ORR of 74% (95% confidence interval 65%-82%). Twelve (15%) pts had stable disease. Median PFS and OS were 5.3 and 9.5 months, respectively. The 1-year OS was 36%. Grade 3/4 myelosuppression was the most common toxicity (thrombocytopenia 44%, neutropenia 34%, febrile neutropenia 12%, anemia 26%), but was manageable. Severe non-hematologic toxicities (&gt;5%) included hypokalemia 17%, fatigue 13%, dehydration 10%, hyponatremia 10%, pneumonia 9%, and nausea/vomiting 8%. 1 pt died from sepsis and another from aspiration pneumonia. Conclusions: First-line ES-SCLC treatment with amrubicin and carboplatin induced several complete responses and is considered highly active. Myelosuppression was managed effectively with growth factor support. These results are comparable to historical data with platinum-doublet chemotherapy. A larger randomized study would be required to best assess this regimen’s impact on survival.
Anti-GD2 monoclonal antibody 3F8 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) for primary refractory neuroblastoma (NB) in bone marrow (BM)
Authors: B. H. Kushner, K. Kramer, S. Modak, N. V. Cheung
Journal: Journal of Clinical Oncology (2007)

9502 Background: Despite high-dose chemotherapy, NB in BM often persists and forebodes death. Methods: 3F8/GM- CSF was used in 63 patients (pts) with NB in BM by morphology and/or metaiodobenzylguanidine (MIBG) scan, no prior progressive disease or immunotherapy, and no soft tissue NB; 35 (56%) of the pts had received second-line therapy and 24 (38%) were post-transplant. Treatment was repeated if human anti-mouse antibody (HAMA) titer was low. Results: Of 30 pts with NB in BM but normal MIBG scans (Group 1), 25 (83%) had complete response (CR) after cycle 1 (n=17), cycle 2 (n=5), or cycle 3, 6, or 7 (one pt each), including 13/16 post-transplant pts. Among 15 pts with NB in BM and abnormal MIBG scans (Group 2), 12 (80%) had CR in BM after cycle 1 (n=5), cycle 2 (n=4), cycle 4 (n=2), or cycle 9 (n=1); MIBG scans normalized in 5/11 pts who had multiple abnormal MIBG(+) sites and in 4/4 pts who had one abnormal MIBG(+) site (irradiated in three pts). Of 18 pts who had abnormal MIBG scans but no NB seen in BM tests (Group 3), 14 (78%) had CR or near CR, including eight whose MIBG(+) sites were irradiated. Early HAMA limited treatment in 19 pts, but was prevented by high-dose cyclophosphamide. CR continues in 12 pts (five never transplanted) with long follow-up (20+ -to- 146+ months) and in 10 pts with short follow-up. The only common toxicities of this outpatient treatment were pain and hives; there were no long-term toxicities. Conclusions: 3F8/GM-CSF is well tolerated, achieves a high CR rate against primary refractory NB in BM (including post-transplant), and may prolong disease control in non- transplanted pts. Further experience will show whether it ought to be used for consolidative therapy in place of myeloablative cytoreduction. No significant financial relationships to disclose.
A randomized phase II trial comparing two doses of lenalidomide for the treatment of stage IV ocular melanoma
Authors: J. B. Zeldis, C. Heller, G. Seidel, N. Yuldasheva, D. Stirling, Y. Shutack, S. K. Libutti
Journal: Journal of Clinical Oncology (2009)

e20012 Background: Ocular melanoma is the most common primary intraocular malignancy in adults with an incidence of 4.3 new cases per million. Approximately 50% of patients will develop metastases and the mean survival of those with liver metastases is 8–10 months. There are no effective systemic therapies. Pre-clinical studies of the antiangiogenic and immunomodulatory agent, lenalidomide, have shown promise in animal models of human ocular melanoma. We therefore conducted a phase II trial comparing two doses of oral lenalidomide. Methods: Patients with stage IV ocular melanoma, who met eligibility criteria and demonstrated disease progression, were enrolled on an IRB approved prospective random assignment trial comparing 5 mg and 25 mg of lenalidomide administered once a day orally for 21 days with a 7 day recovery (one cycle). Lesions were measured at baseline and every 3 months and scored for response by RECIST criteria. Patients who completed 3 cycles were eligible for response evaluation. Patients with responding lesions or with stable disease could continue receiving the agent. Toxicity was assessed using the NCI Common Toxicity Criteria. Results: Seventeen patients (13 female, 4 male; mean age 53) met eligibility criteria and were randomized to 5 mg (9 patients) or 25 mg (8 patients) of lenalidomide. The agent was well tolerated at both doses with only three grade 3 toxicities (two decreased ANC and one rash/puritis) requiring dose adjustments. Sixteen patients were eligible for response assessments. Nine patients had progressive disease by RECIST criteria following 3 cycles of therapy. Seven patients (44%) had stable disease for a mean of 7 months (range 6–12 months). There were no RECIST defined responders. There were no differences between the two dose groups with respect to toxicity or disease stabilization. Conclusions: Lenalidomide is well tolerated at doses of 5 mg and 25 mg orally for a 21 day cycle by patients with stage IV ocular melanoma. While no responses were seen, disease stabilization for a mean of 7 months was seen in 44% of patients. This effect was consistent with the pre-clinical animal data. Based on these results, further development of lenalidomide in combination with other agents should be considered for the treatment of metastatic ocular melanoma. [Table: see text]
Abstract 15773: Sodium Restriction Activates the Renin-angiotensin-aldosterone System but Fails to Improve Heart Failure or Survival in Experimental Dilated Cardiomyopathy
Authors: Ranjana Tripathi, Ryan Sullivan, Michael Fan, Nelson Houng, Inna P Gladysheva, Guy L Reed
Journal: Circulation (2016)

Introduction: Dilated cardiomyopathy (DCM) causes progressive heart failure (HF), which affects millions of Americans. Dietary sodium restriction is recommended by AHA/ACC guidelines to reduce the ...
Preoperative evaluation of epithelial ovarian cancer with multidetector computed tomography and its correlation with surgical outcome
Authors: C. SH, S. Thulkar, D. Srivastava, L. Kumar, R. Hariprasad, S. Kumar, M. Sharma
Journal: Journal of Clinical Oncology (2007)

16051 Background: In the management of epithelial ovarian cancer (EOC), optimum debulking surgery (residual tumour of 1 cm or less) is the most important prognostic factor and is associated with higher survival We conducted a prospective study to evaluate the role of Multidetector (MD) CT scan to predict optimal debulking in advanced EOC. Methods: Between December, 2004 and October, 2006, 38 previously untreated patients (median age-50 years, range 26 to 70) were evaluated with contrast- enhanced MD CT scan of abdomen and pelvis. All CT scans were performed on four-slice MD CT scanner with thin slice image acquisition. Multiplanar coronal, sagital or oblique images were constructed and all images were reviewed by at least 2 radiologists. The extent of disease was determined and mapped for all areas of abdomen and pelvis. Patients underwent primary debulking surgery in which total abdominal hysterectomy, bilateral salphingo-oophorectomy, omentectomy and optimal cytoreduction was done. CT scan films were reviewed and compared with surgical findings. A CT scan scoring system was developed to predict the optimum debulking using 10 parameters: ascites, pelvic, peritoneal deposits, large bowel, small bowel, omentum, diaphragm, liver, lymphadenopathy and lesser sac. Each factor was assigned a score of 0 to 2. The statistical analysis was done using SPSS version 11 and EpiInfo 6 software. Results: The mean interval between CT scan and surgery was 11 days. 18 of 38 patients had a CT score = 7; all 18 had sub-optimal debulking. Of remaining 20 patients with CT score &lt;7, 17(44.7%) had optimum and 3 had sub-optimal cytoreduction. The sensitivity and specificity was 85.7% (95% CI 62.6–96.2) and 100% (95% CI 77.1–100), respectively. It had positive predictive value of 100% and negative predictive value of 85% with accuracy of 92% in identification of patients who would not benefit from surgery. Presence of tumor at gall bladder fossa, porta hepatis, ligament teres, spleen , stomach, pancreas, lesser sack and pelvic side walls was associated with sub-optimal debulking. Conclusions: Pre-operative CT scan scoring helps to identify patients who are likely to have sub-optimal debulking and may be candidates for neoadjuvant chemotherapy No significant financial relationships to disclose.
The double empathy problem, camouflage, and the value of expertise from experience
Authors: Peter Mitchell, Sarah Cassidy, Elizabeth Sheppard
Journal: Behavioral and Brain Sciences (2019)

Abstract To understand why autistic people are misperceived in the way Jaswal &amp; Akhtar suggest, we should embrace concepts like the “double empathy problem” and camouflaging and recognize the negative consequences these have for mental health in autism. Moreover, we need to value expertise from experience so that autistic people have a voice and indeed a stake in research into autism.
Video linked medical oncology clinics: A novel way to improve patients’ access to medical oncology services in rural Australia
Authors: I. Marr, S. Sabesan
Journal: Journal of Clinical Oncology (2009)

e17573 Background: To improve the access of Mt Isa patients to medical oncologists, Townsville Cancer Centre runs weekly medical oncology clinics via videolink. Aim of this study was to assess patient satisfaction, safety of chemotherapy delivery, and cost effectiveness of such technology. Methods: Between 2006 and 2008, 42 patients were seen. A questionnaire based survey was conducted by telephone to assess patient's level of satisfaction and quality of communication. Safety of chemotherapy delivery was evaluated by retrospective chart audit. Results: 25 patients completed the questionnaire. Six were new patients and the rest were for review leading to more than 90 encounters. Satisfaction: 100% of those interviewed were satisfied with the care given by the Townsville Cancer Centre. Of these 88% felt they developed a friendly relationship with the specialist. 90% felt medication could be taken without any concerns after videolink. 27% of patients interviewed felt examination was needed by the specialist, but 92% of the patients would rather see the specialist via videolink than travel to Townsville. Overall 96% felt it saved time, money and was convenient. Responses, apart from the question about the need for physical examination by the specialist, were more than 80% in agreement. Safety: 32 patients received active therapy. 60% were treated with palliative intent and the rest adjuvant. The median number of cycles was 5 (1–8). A total of 4 patients were admitted for complications- 2 for febrile neutropenia and 2 for emesis.There were no treatment related deaths. Cost effectiveness: Factors for consideration were cost of patient and specialist travel and accommodation,cost of interruption of routine clinics at specialists’ home, cost of video link apparatus and maintenance and cost of disturbance of quality of life for patients and doctors resulting from travel. Conclusions: Satisfaction with video linked clinics is high. It saves travel time for the patients and specialists and seems to be cost effective. It is safe to supervise chemotherapy administration using this technology. Therefore, this method of service delivery could be adopted by medical oncology departments to improve services to the rural and remote areas. No significant financial relationships to disclose.
Therapeutic endoscopic ultrasound for postoperative fluid collections: a surgeon’s best friend
Authors: David L. Diehl
Journal: Endoscopy (2019)

Endoscopic ultrasound (EUS) has become an essential diagnostic modality because of its ability to identify targets for fine needle aspiration (FNA) that are not easily seen or accessible through other means. The next level of indispensability for EUS was achieved with the development of a means of accessing and draining intra-abdominal and retroperitoneal fluid collections, usually pseudocysts [1]. No longer was an endoscopically visible bulge required to successfully achieve internal drainage [2]. EUS-guided cystgastrostomy or cystduodenostomy has emerged as the preferred method for management of pancreatic walled-off necrosis (WON). Since the early reports, EUS-guided treatment of WON has been a rewarding area of growth in the field.
Male Pubertal Timing—Boys Will Be Men, but When?
Authors: Vanessa A. Curtis, David B. Allen
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
A phase I study of antitumor vaccination using tumor cells genetically modified to express alpha(1,3)galactosyltransferase (αGT) in patients with refractory or recurrent non-small cell lung cancer (NSCLC)
Authors: J. C. Morris, J. E. Janik, N. Vahanian, S. Mertes, D. O’Hagan, L. Tennant, S. Pittaluga, P. Albert, T. Seregina, C. Link
Journal: Journal of Clinical Oncology (2006)

12503 Background: Despite new treatments, lung cancer remains the leading cause of cancer death. We examined the safety and activity of antitumor vaccination using genetically altered human non-small cell lung cancer cells (HAL; HyperAcute Lung Cancer Vaccine) engineered to express xenotransplantation antigens through retroviral transfer of the murine αGT gene in patients (Pts.) with NSCLC. Methods: A single institution Phase I trial. Eligibility: Stage IV, recurrent or progressive NSCLC, Age ≥18, ECOG PS ≤2, prior chemotherapies ≤2, AGC ≥1,500/μL, Plts. ≥100,000/μL, adequate hepatic/renal function and informed consent. Cohorts of Pts. received intrademal injections of 3 × 10 6 , 10 × 10 6 , 30 × 10 6 , or 100 × 10 6 HAL vaccine cells every 4-weeks × 4, or 500 × 10 6 HAL cells followed by 300 × 10 6 HAL cells every 2-weeks × 7. Toxicity was assessed using CTCv3.0 and response by RECIST criteria. Immunological responses included anti-αGal antibody titers, interferon-γ ELISPOT and vaccine site skin biopsies. Results: Seventeen Pts., 9 men and 8 women, median age 57 years (range, 34–85), median number of prior chemotherapies 1 (range, 1–2) were vaccinated. There were no Grade 3/4 adverse events attributable to the study vaccine. Adverse events (≤grade 2) attributable to vaccination include injection site urticaria, pain/discomfort, local skin reaction, fatigue, herpes zoster, arthralgias/myalgias and hypertension. Six Pts. had stable disease ≥16 weeks duration (range, 16–85+ weeks), 9 Pts. progressed and 2 Pts. were not evaluable for response. Skin biopsies 48-hrs after vaccination demonstrated vaccine cells in the dermis with acute infiltration of lymphocytes, granulocytes and eosinophils. Serum anti-αGal titers increased 10–14 fold with vaccination. Conclusions: Xenogeneic antitumor vaccination with genetically altered allogeneic human lung cancer cells expressing αGT is safe and feasible. A phase II trial is planned. No significant financial relationships to disclose.
AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Authors: Matthew R. Gardner, Christoph H. Fellinger, Lisa M. Kattenhorn, Meredith E. Davis-Gardner, Jesse A. Weber, Barnett Alfant, Amber S. Zhou, Neha R. Prasad, Hema R. Kondur, Wendy A. Newton, Kimberly L. Weisgrau, Eva G. Rakasz, Jeffrey D. Lifson, Guangping Gao, Nancy Schultz-Darken, Michael Farzan
Journal: Science Translational Medicine (2019)

AAV-expressed eCD4-Ig protects rhesus macaques from SIVmac239.
Targeted therapy for osteosarcoma using 17AAG and rapamycin: Identification of new targets using Gene Microarray profiling and MiRNA
Authors: Y. Gazitt, K. Moncada, C. Thomas, C. Takimoto, A. Tolcher
Journal: Journal of Clinical Oncology (2007)

10027 Background: Sarcomas constitute a group of diverse diseases with many subtypes and varying prognoses. Hence, new approaches for therapy involving targeting of specific survival pathways are needed. Methods: We used 17-AAG to block HSP90 and rapamycin (Ra) to block mTOR, in 2 osteosarcoma cell lines, HOS and KHOS/NP. Cells were treated for 24 and 48 hours with 200 nM of 17- AAG or 5 micromolar of rapamycin. Gene profiling (GP) was performed using h-U133 2 Plus Array (Affymetrix). Results were pre-filtered using the GCOS pair-wise comparisons. ANOVA was filtered for &gt;2-fold change between two conditions. We compared control HOS or KHOS vs. 24 H or 48 H treatment with Ra, or 17AAG. Gene identity, ontology and z-scores were derived. For micro RNAs (miRs), we used a miRNA chip (LC Sciences) and data were normalized, adjusted and clustered using t-test (p&lt;0.01). Results and Conclusions: 17-AAG is a good inducer of apoptosis in HOS and KHOS cells (IC50 of ∼50nM) and blocked cells at mitosis. Ra is a weak inducer of apoptosis (IC20 at 5 micromolar) and blocked cells at G1. GP of 17AAG treated HOS/KHOS cells revealed &gt;1,000 and 1,600 gene changes at 24 H and 48 H, respectively, with ∼700 genes affected at 24 and 48H. Ra affected ∼400 and ∼350 genes at 24 and 48H, respectively, with 20 genes affected at 24 and 48H. Of the genes upregulated by 17AAG, &gt;450 were in cell and protein metabolism; &gt;50 genes were in chromatin modifications and &gt;40 in regulation of cell cycle. With 17AAG, changes were found in histones and deacetylases; cytoskeleton proteins; extracellular matrix proteins and MMPs; HSPs; MAP kinase, mTOR, IGF and VEGF pathways; cell cycle and apoptosis. Many targets were validated by by immunoblotting. MiRs were profiled following 24H treatment with 17AAG or Ra. 17AAG upregulated miR122a;145;143 and 663 (4–16 fold) and miR 542–5P was decreased (∼12 fold). Ra upregulated miR 498;145;143;452;663; 602 and miR224 (4–32 fold) and downregulated (4–32 fold) miR1;542–5P and miR335. Taken together, miR changes affect the expression of transcripts related to angiogenesis; cell cycle; cell signaling and apoptosis and are common to the changes observed by GP. In summary, new therapeutic targets were identified by the combination of GP and miRNA following 17AAG or rapamycin. No significant financial relationships to disclose.